{{medical}}
{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 457784738
| IUPAC_name = 4-chloro-''N''-(2-morpholin-4-ylethyl)benzamide
| image = Moclobemide.svg
| width = 250
| image2 = Moclobemide3Dan.gif
| width2 = 225
<!--Clinical data-->
| tradename = Amira, Aurorix, Clobemix, Depnil, Manerix
| Drugs.com = {{drugs.com|CONS|moclobemide}}
| pregnancy_AU = B3
| legal_AU = S4
| legal_CA = Rx-only
| legal_UK = POM
| legal_status = 
| routes_of_administration = oral
<!--Pharmacokinetic data-->
| bioavailability = 55-95% (increases with repeat administration)<ref>{{cite journal|last=Fitton|first=A|author2=Faulds, D |author3=Goa, KL |title=Moclobemide. A review of its pharmacological properties and therapeutic use in depressive illness|journal=Drugs|date=April 1992|volume=43|issue=4|pages=561–596|pmid=1377119|doi=10.2165/00003495-199243040-00009}}</ref>
| protein_bound = 50%<ref name = MAOA>{{cite journal|last=Schoerlin|first=MP|author2=Mayersohn, M |author3=Korn, A |author4= Eggers, H |title=Disposition kinetics of moclobemide, a monoamine oxidase-A enzyme inhibitor: single and multiple dosing in normal subjects|url=https://archive.org/details/sim_clinical-pharmacology-and-therapeutics_1987-10_42_4/page/395|journal=Clinical Pharmacology and Therapeutics|date=October 1987|volume=42|issue=4|pages=395–404|pmid=3665338}}</ref>
| metabolism = [[Hepatic|Hepatic]]
| elimination_half-life = 1-2 hours, 4 hours (elderly)<ref name = Lancet>{{cite journal|last=Freeman|first=H|date=December 1993|title=Moclobemide|journal=Lancet|volume=342|issue=8886-8887|pages=1528–1532|doi=10.1016/S0140-6736(05)80090-X|pmid=7902906}}</ref><ref>{{cite journal|last=Gex-Fabry|first=M|author2=Balant-Gorgia, AE |author3=Balant, LP |title=Potential of concentration monitoring data for a short half-life drug: analysis of pharmacokinetic variability for moclobemide|journal=Therapeutic Drug Monitoring|date=February 1995|volume=17|issue=1|pages=39–46|pmid=7725375|doi=10.1097/00007691-199502000-00007}}</ref>
| excretion = [[Renal|Renal]], [[Faeces|Faecal]] (<5%)<ref name = MAOA />
<!--识别信息-->
| IUPHAR_ligand = 7428
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 71320-77-9
| ATC_prefix = N06
| ATC_suffix = AG02
| PubChem = 4235
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
 | DrugBank = DB01171
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4087
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = PJ0Y7AZB63
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02561
| ChEBI_Ref = {{ebicite|changed|EBI}} 
| ChEBI = 83531
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 86304
<!--化学（分子）信息-->
| C=13 | H=17 | Cl=1 | N=2 | O=2 
| molecular_weight = 268.739 g/mol
| smiles = Clc1ccc(cc1)C(=O)NCCN2CCOCC2
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C13H17ClN2O2/c14-12-3-1-11(2-4-12)13(17)15-5-6-16-7-9-18-10-8-16/h1-4H,5-10H2,(H,15,17)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = YHXISWVBGDMDLQ-UHFFFAOYSA-N
}}
'''吗氯贝胺'''（商品名也作'''Amira'''、'''Aurorix'''、<ref name="pmid8023056">{{cite journal |author=Scheen AJ |title=[Drug of the month. Moclobemide (Aurorix)] |language=fr |journal=Rev Med Liege |volume=49 |issue=5 |pages=291–2 |date=May 1994 |pmid=8023056 }}</ref>'''Clobemix'''、'''Depnil'''或'''Manerix'''）是主要用于治疗抑郁症和社交焦虑的单胺氧化酶A（RIMA）药物的可逆抑制剂。<ref name="pmid8875133"/>它在[[美国|美国]]不被允许使用，但在其它西方国家，例如[[英国|英国]]和[[澳大利亚|澳大利亚]]（TGA于2000年12月）是被批准使用的。<ref name=SANDOZ>{{cite web|title=PRODUCT INFORMATION MOCLOBEMIDE SANDOZ® 150mg and 300mg TABLETS|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-01146-3|work=TGA eBusiness Services|publisher=Sandoz|accessdate=16 October 2013|date=6 March 2012|archive-date=2020-09-21|archive-url=https://web.archive.org/web/20200921165506/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-01146-3|dead-url=no}}</ref>它由[[罗氏|罗氏]]公司的附属公司生产。起初，Aurorix也在[[南非|南非]]由罗氏公司供应，但在专利期满之后撤回，Cipla Medpro's Depnil和Pharma Dynamic's Clorix的成本减半。

当吗氯贝胺与胺类混用时，如含[[酪胺|酪胺]]的食物或升压胺类药物，不会出现显著的血压升高，这与较老的非选择性和不可逆单胺氧化酶抑制剂（MAOI）不同，后者的混用会导致血压严重上升。由于不会造成[[抗胆碱剂|抗胆碱剂]]、心血管、认知与精神运动损伤，吗氯贝胺在老年人以及心血管疾病患者中是有利的。<ref name="pmid8875133">{{cite journal |vauthors=Fulton B, Benfield P |title=Moclobemide. An update of its pharmacological properties and therapeutic use |journal=Drugs |volume=52 |issue=3 |pages=450–74 |date=September 1996 |pmid=8875133 |doi=10.2165/00003495-199652030-00013}}</ref>

==参考文献==
{{reflist}}

==拓展阅读==
*Scientific Information on Aurorix (German)
*[http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=189524 PubChem Substance Summary: Moclobemide]{{Wayback|url=http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=189524 |date=20130617171523 }} National Center for Biotechnology Information.
{{抗抑郁药}}
{{ADHD_pharmacotherapies}}
[[Category:抗抑郁药物|Category:抗抑郁药物]]
[[Category:单胺氧化酶抑制剂|Category:单胺氧化酶抑制剂]]
[[Category:氯苯|Category:氯苯]]
[[Category:苯甲酰胺|Category:苯甲酰胺]]
[[Category:吗啉|Category:吗啉]]